Patient Guide: A Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing With GW679769 (50 mg or 150 mg) for Three Consecutive Days When Administered With a Single Intravenous Dose of Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects With Known Risk Factors for Post-operative Nausea and Vomiting Who Are Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated With an Increased Emetogenic Risk

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • ✓ Get matched to the right study location for you
  • ✓ Connect directly with study coordinators at multiple participating sites
  • ✓ Understand eligibility with our simplified screening tool
  • ✓ Free service - we're here to help you access clinical research
Trial ID: NCTNCT00274690
Status: COMPLETED
Condition: Postoperative Nausea and Vomiting
Phase: Phase II

Loading interactive enrollment tools...

The full interactive experience will load momentarily